Behçet Uveitis

Refractory Ocular Behçet’s Disease; Outcome of Low Dose Infliximab

“…The incidence of posterior segment involvement is 50-93% [17]. Late complications include cataract, iris synechia, glaucoma, retinal vascular occlusion and neo-vascularization, and optic atrophy [18]. In the current case, the patient developed bilateral intermediate uveitis, central retinitis, cataract, and a macular hole.…”

“…For OBD, systemic or local corticosteroids are advised; when insufficient, systemic immunomodulatory therapy [8,18,19,23,24] and tumor necrosis factor alpha (TNF-α) inhibitor [11,22]. Even with intensive immunosuppressive therapy, however, ocular inflammation may relapse in about 70% of patients, resulting in permanent loss of vision.…”

Knitting the Threads of Silk through Time: Behçet’s Disease—Past, Present, and Future

“…The eye is the most common vital organ involved in BD [ 90 ] and over two-thirds of patients will develop ocular inflammation, most often bilateral panuveitis or retinal vasculitis [ 91 ]. Ocular manifestations include nongranulomatous iridocyclitis, chorioretinitis, or residual lesions suggesting previous iridocyclitis or chorioretinitis such as posterior synechia, complicated cataracts, lens pigmentation, chorioretinal atrophy, optic nerve atrophy, and secondary glaucoma.…”

“…One of the groundbreaking discoveries of late is the recognition that BD may be diagnosed solely based on ocular findings alone in the absence of systemic manifestations [ 90 ] using the state-of-the-art imaging technologies, and this is extremely important as ocular manifestation may be the first presenting manifestations in 10–15% of BD patients [ 180 ]. The ultimate goal in eye disease is to sustain remission with preservation of vision [ 91 ]. Recent studies support earlier and more frequent consideration for biological therapy in Behçet's uveitis [ 91 ] but questions remain regarding when to use them in patients with uveitis alone and with classical uveitis characteristics but not fulfilling the international criteria for BD.…”

“…The ultimate goal in eye disease is to sustain remission with preservation of vision [ 91 ]. Recent studies support earlier and more frequent consideration for biological therapy in Behçet's uveitis [ 91 ] but questions remain regarding when to use them in patients with uveitis alone and with classical uveitis characteristics but not fulfilling the international criteria for BD. Steroids, while able to rapidly control acute flares, are not able to reduce recurrence rates and their prolonged use is associated with serious side effects.…”